Scarica l'app Stockscreener
11.92
4.56%
0.52
Precedente Chiudi:
$11.40
Aprire:
$11.41
Volume 24 ore:
589.07K
Relative Volume:
2.16
Capitalizzazione di mercato:
$596.02M
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
-12.96
EPS:
-0.92
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
+7.48%
1M Prestazione:
+5.49%
6M Prestazione:
+27.35%
1 anno Prestazione:
+44.66%
Intervallo 1D:
$11.41
$11.99
Intervallo di 1 settimana:
$11.04
$11.99
Portata 52W:
$7.88
$11.99
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Confronta TBPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
11.92 | 570.02M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Iniziato | BTIG Research | Buy |
| 2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Theravance Biopharma Reports Strong Q2 2025 Results - TipRanks
Theravance Sales Jump 83 Percent - The Motley Fool
Theravance Biopharma (TBPH): A High-Conviction Play on Rare Disease Innovation and Durable Cash Flow - AInvest
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics - AInvest
Theravance Biopharma's Q2 Surge: A Case Study in Biotech Resilience and Strategic Precision - AInvest
Earnings call transcript: Theravance Biopharma Q2 2025 earnings beat expectations - Investing.com
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Theravance Bio: Q2 Earnings Snapshot - San Francisco Chronicle
Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples - Investing.com Canada
Theravance Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
THERAVANCE BIOPHARMA Earnings Results: $TBPH Reports Quarterly Earnings - Quiver Quantitative
Theravance Biopharma earnings beat by $0.41, revenue topped estimates - Investing.com Canada
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Is Theravance Biopharma Inc. still worth holding after the dipFree Smart Money Tracking Signal Generator - Newser
Technical signs of recovery in Theravance Biopharma Inc.Daily Profit Watch With Forecast Confidence - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedTrend Confirmation Scanner with Entry Focus - Newser
Signal strength of Theravance Biopharma Inc. stock in tech scannersRisk Aware Trading Ideas with Alert Levels - Newser
Real time pattern detection on Theravance Biopharma Inc. stockIntraday Signal Forecast for Fast Traders - Newser
What institutional flow reveals about Theravance Biopharma Inc.Smart Forecast Signals from AI Models - Newser
Price momentum metrics for Theravance Biopharma Inc. explainedFree News Based Entry Opportunity Alerts - Newser
Tools to monitor Theravance Biopharma Inc. recovery probabilitySwing Watchlist With Tight Stop Placement - Newser
Using data models to predict Theravance Biopharma Inc. stock movementSmart Stock Forecast Using AI Algorithms - Newser
Theravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Moving Average Trends for Theravance Biopharma Inc. Stock: What They IndicateTechnical Entry Plan with Risk Minimization - Newser
Theravance Biopharma Inc expected to post earnings of 67 cents a shareEarnings Preview - TradingView
Theravance Biopharma Inc. Stock Performance After Earnings: Historical InsightsFree Conservative Entry for High Return Setup - Newser
What makes Theravance Biopharma Inc. stock price move sharplyHigh Conviction Screener with Trend Matching - Newser
How Theravance Biopharma Inc. stock performs during market volatilitySmart Trade Forecast Based on Neural Logic - Newser
Technical Charts Suggest Momentum Shift in Theravance Biopharma Inc.Chart Driven Price Action Analysis - beatles.ru
What’s the recovery path for long term holders of Theravance Biopharma Inc.Free ROI Boosting Trade Opportunity Calendar - Newser
What is the dividend policy of Theravance Biopharma Inc. stockInvest confidently with professional market insights - Jammu Links News
Is Theravance Biopharma Inc. stock overvalued or undervaluedInvest confidently with actionable market data - Jammu Links News
What are the latest earnings results for Theravance Biopharma Inc.Maximize gains with timely market signals - Jammu Links News
What are the technical indicators suggesting about Theravance Biopharma Inc.High-velocity gains - Jammu Links News
How volatile is Theravance Biopharma Inc. stock compared to the marketBreakthrough profits - Jammu Links News
What analysts say about Theravance Biopharma Inc. stockSuperior returns - Jammu Links News
Should I hold or sell Theravance Biopharma Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What is Theravance Biopharma Inc. company’s growth strategyMaximize your gains with professional insights - Jammu Links News
What drives Theravance Biopharma Inc. stock priceAchieve rapid returns with smart investment plans - Jammu Links News
How strong is Theravance Biopharma Inc. company’s balance sheetAchieve breakthrough results with expert guidance - Jammu Links News
Why is Theravance Biopharma Inc. stock attracting strong analyst attentionHigh-profit capital plays - Jammu Links News
What earnings revisions data tells us about Theravance Biopharma Inc.AI Generated Momentum Stock Forecast Guide - Newser
Applying Wyckoff theory to Theravance Biopharma Inc. stockSwing Entry Insight With Forecast Accuracy - Newser
Theravance Biopharma Inc. stock chart pattern explainedWeekly High Conviction Trade Setup Analysis - Newser
Published on: 2025-08-02 07:06:55 - beatles.ru
Using RSI to spot recovery in Theravance Biopharma Inc.Free Pattern Breakout Entry Stock Forecast - Newser
Bank of New York Mellon Corp Boosts Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Using Ichimoku Cloud for Theravance Biopharma Inc. technicalsFree Low Capital High Return Stock Plans - Newser
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):